Our core expertise is in M&A, partnerships and private placements, and we focus exclusively on life science companies including biotechnology, big pharma, specialty pharma, medical devices, research tools and diagnostics. We’ve highlighted below some of our transactions that show our range of experience in these areas.

$35,500,000

Acquisition by Ligand

Acquisition by Ligand

press release
$250,000,000

Fairness Opinion


Fairness Opinion on CTP-656 Acquisition by Vertex

press release
$75,000,000+

Acquisition by Boston Scientific

Sale of GI medical device company to Boston Scientific for $75 million plus commercial milestones

press release
$2,100,000,000

Partnership with AstraZeneca

Collaboration with AstraZeneca to develop and commercialize Anticalin-based inhaled treatments for respiratory diseases.

press release
$70,000,000

N. & S. America and India Partnership with Metuchen

Avanafil Partnership with Metuchen Pharmaceuticals LLC

press release
$461,000,000

Partnerships with Auxilium, Menarini & Sanofi

North American, European, and ROW partnerships with Auxilium, Menarini, and Sanofi for erectile dysfunction drug Stendraâ„¢ (avanafil) totaling $461 million plus royalties

press release
$150,000,000

Preferred Stock

Private financing for a private, late-stage precision medicine company developing dalcetrapib to be the first genetically targeted medicine in cardiovascular disease

press release
$43,400,000

Series B Preferred Stock & Debt

$43.4 million Series B expansion capital for private, commercial-stage hip and knee implant company

press release
$50,000,000

Strategic Investment by Baxter

$50 million equity financing by Baxter (prior to European partnership) for oncology company

press release
$320,000,000

Acquisition of Zoladex

Acquisition of Zoladex from AstraZeneca

press release
$476,000,000

Acquisition of Performance Optics

Buyside representation on the acquisition of leading global eyeglass lens manufacturing company.
(pending)

press release
$337,500,000

Acquisition of SPL

Acquisition of Scientific Protein Laboratories (SPL) for $337.5 million by Shenzhen Hepalink Pharmaceutical Co., Ltd.

press release